Given the inherent degree of DNA repair deficiencies in MCL, poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors have been thought of as promising targets in producing synthetic lethality based on PARP-1′s role in DNA repairs. This evidence concerns the gene PARP1 and mantle cell lymphoma.